Ascendis Pharma A/S (NASDAQ:ASND) is a biopharmaceutical company focused on developing therapies for rare diseases. The company uses its TransCon technology to create long-acting prodrugs, aiming to improve patient outcomes. In the competitive landscape,
Ascendis faces peers like argenx SE, Apellis Pharmaceuticals, BeiGene, and Blueprint Medicines, all striving to innovate in the biopharmaceutical sector. In evaluating capital efficiency, Ascendis Pharma’s ROIC of -50.64% against a WACC of 6.11% results in a ROIC to WACC ratio of -8.29. This indicates that Ascendis is not generating sufficient returns on its invested capital to cover its cost of capital, highlighting inefficiencies in capital utilization.
Comparatively, argenx SE (ARGX) shows a ROIC of -4.67% and a WACC of 4.99%, leading to a ROIC to WACC ratio of -0.94. Despite being negative, ARGX’s ratio is the least negative among its peers, suggesting it is closer to achieving capital efficiency. This positions argenx as a relatively better performer in managing its capital.
Apellis Pharmaceuticals (APLS) and BeiGene (BGNE) also exhibit negative ROIC to WACC ratios of -3.85 and -1.28, respectively. These figures indicate that both companies, like Ascendis, are struggling to generate returns that exceed their cost of capital, though they perform better than Ascendis in this regard.
Blueprint Medicines (BPMC) has a ROIC of -17.59% and a WACC of 8.45%, resulting in a ROIC to WACC ratio of -2.08. While still negative, BPMC’s ratio is more favorable than Ascendis, suggesting slightly better capital management. Overall, these companies face challenges in achieving positive returns on their invested capital relative to their costs.